We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Oxycodone Hydrochloride Injection in the Postoperative Pain Relieving Treatment

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01304134
First Posted: February 25, 2011
Last Update Posted: August 11, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Mundipharma (China) Pharmaceutical Co. Ltd
  Purpose
To determine the efficacy and safety of oxycodone i.v. patient-controlled analgesia (PCA) in the pain relieving treatment during 48h postoperative period, by comparing with morphine i.v. PCA.

Condition Intervention Phase
Other Acute Postoperative Pain Drug: Oxycodone Drug: Morphine Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Blind, Multicentre, Parallel Group Study to Investigate the Efficacy and Safety of Oxycodone Hydrochloride Injection in the Postoperative Pain Relieving Treatment

Resource links provided by NLM:


Further study details as provided by Mundipharma (China) Pharmaceutical Co. Ltd:

Primary Outcome Measures:
  • Measuring VAS [ Time Frame: 3h post-operation ]
    Measuring resting and coughing VAS, assessing the intensity of pain

  • Measuring VAS [ Time Frame: 24 hours post operation ]
    Measuring resting and coughing VAS, assessing the intensity of pain

  • Measuring VAS [ Time Frame: 48 hours post operation ]
    Measuring resting and coughing VAS, assessing the intensity of pain


Secondary Outcome Measures:
  • Dosage [ Time Frame: Within 48h ]
    Total dosage of study drugs within 48h.

  • The dosage of other rescue analgesic drugs used within 48h post-operation. [ Time Frame: 48hrs ]
    The dosage of other rescue analgesic drugs used within 48h post-operation.

  • The invalid times and the total times of PCA application [ Time Frame: 48hrs ]
    The invalid times and the total times of PCA application

  • Satisfaction degree for analgesia [ Time Frame: 48hrs ]
    Satisfaction degree for analgesia after the treatment

  • AE occurrence and abnormal lab value [ Time Frame: 48hrs ]
    AE and normal lab value will be recorded during the study


Enrollment: 240
Study Start Date: March 2010
Study Completion Date: August 2010
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Oxycodone i.v.
To determine the efficacy and safety of oxycodone i.v. patient-controlled analgesia (PCA)
Drug: Oxycodone
dosage:10mg/l dosage form:injection frequency:via PCA pump, background rate:0.5ml/h, 2ml/time duration:48 hours
Other Name: Oxycodone Injection
Active Comparator: Morphine i.v.
To determine the efficacy and safety of oxycodone i.v. patient-controlled analgesia (PCA)
Drug: Morphine
dosage: 10mg/ml dosage form: injection frequency: via PCA pump, background rate: 0.5ml/h, 2ml/times duration: 48 hours
Other Name: Morphine Injection

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients of either sex aged 18 to 65 years old, with a standard body weight [standard body weight = height (cm) - 100] ±15%.
  2. ASA I and II.
  3. Scheduled on elective open upper abdominal surgery under general anesthesia (liver, gall bladder, spleen, stomach, kidney, colon surgery), of which predicted operation duration is between 2-4h.
  4. Hospitalized patients on non-emergency condition who have been given appropriate preoperative treatments.
  5. Patients who are willing to participate in the study and have signed the written informed consent.
  6. Negative pregnancy test result should be obtained for women of child-bearing age.

Exclusion Criteria:

  1. Long-term analgesics or psychotropic drugs (including opioids, NSAIDs, sedatives, antidepressants) taken for the chronic pain, or patients abusing alcohol.
  2. Body weight is less than or over ±15% of the standard body weight.
  3. Severe impairment of liver and renal function at preoperative stage (ALT, AST, BUN, Cr).
  4. Medical history of recovering from abnormal surgery anesthesia.
  5. Medical history of hypertension (Systolic blood pressure ≥180Hg, Diastolic blood pressure 110Hg).
  6. Esophagus reflux disease.
  7. Sedatives, anti-emetics, and anti-pruritic drugs were taken 24 hours before operation.
  8. Have known hypersensitivity to opioids.
  9. Monoamine oxidase inhibitors and antidepressant drugs were taken within 15 days.
  10. Patients with shock.
  11. Patients with COPD.
  12. Patients can not understand the VAS or unable to use PCA.
  13. Pregnant or parturient women.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01304134


Locations
China, Beijing
Investigational site
Beijing, Beijing, China, 100022
Sponsors and Collaborators
Mundipharma (China) Pharmaceutical Co. Ltd
Investigators
Study Chair: Mundipharma China Ltd. Mundipharma China Ltd.
Principal Investigator: Mundipharma China Ltd. Investigational Site Beijing, China
  More Information

Responsible Party: Mundipharma (China) Pharmaceutical Co. Ltd
ClinicalTrials.gov Identifier: NCT01304134     History of Changes
Other Study ID Numbers: OXYI09-CN-302
First Submitted: February 23, 2011
First Posted: February 25, 2011
Last Update Posted: August 11, 2015
Last Verified: August 2015

Additional relevant MeSH terms:
Pain, Postoperative
Pain
Neurologic Manifestations
Nervous System Diseases
Postoperative Complications
Pathologic Processes
Signs and Symptoms
Morphine
Oxycodone
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents